EXPERT OPINION ON INVESTIGATIONAL DRUGS

简称 EXPERT OPIN INV DRUG ·ENGLAND ·出版周期 Monthly ·年均收录 106 篇

4.1

最新影响因子

4.40%

自引率

一般

投稿难度

较慢,6-12周

审稿周期

期刊简介

EXPERT OPINION ON INVESTIGATIONAL DRUGS是一本专注于药物研发领域的国际期刊，ISSN号为1354-3784，由英国出版商TAYLOR & FRANCIS LTD出版，出版地为英国，出版周期为月刊。该期刊的影响因子根据最新数据在药理学与药学领域处于中等水平，目前不是开放获取（OA）期刊，但被SCI收录，并且在中科院分区中通常位于医学或药理学大类的三区或四区。该杂志的发文特点集中于新药研发的早期阶段，包括临床前研究、临床试验设计、药物作用机制以及创新疗法的评估，研究领域涵盖肿瘤学、神经科学、传染病和代谢性疾病等。杂志的质量较高，审稿流程严格，但作为专注于专家观点的期刊，其内容可能偏重综述和评论，原创性研究相对较少，投稿时需注意其对行业前沿观点的偏好以及竞争激烈的发表环境。总体而言，该期刊适合希望了解药物研发动态或发表权威评论的研究者，但需结合自身研究类型和目标谨慎选择。

影响因子趋势

近期发表

Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma 2026-09-18

Safety, pharmacokinetics, pharmacodynamics and target-mediated drug disposition modeling of TST002, a sclerostin antibody, in men and postmenopausal women with low bone mineral density 2026-09-16

Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products 2026-09-10

Varespladib for snakebite envenoming: insights from therapeutic development and clinical trials 2026-09-02

Up and coming early phase CAR T-cell therapy for treating relapsed or refractory large B-cell lymphoma 2026-08-31

HLD-0915: Could it be the breakthrough drug we need for metastatic prostate cancer? 2026-08-27

How can we determine suitable combination immunotherapies for cancer by looking at the molecular targeting of each therapy? 2026-08-12

Telisotuzumab adizutecan for metastatic colorectal cancer: a c-MET-targeted antibody–drug conjugate with a topoisomerase inhibitor payload 2026-08-19

Receptor interacting protein kinase 1 as a potential therapeutic target in inflammatory bowel disease: biological rationale and emerging clinical evidence 2026-08-13

Budigalimab: a viable option for patients with advanced solid tumors 2026-08-03